IGF-1 LR3

Experimental domains documented in the published literature include IGF-1R receptor-binding affinity studies, structure-activity investigations probing the contributions of the R3 substitution and the N-terminal extension to reduced IGFBP affinity, cell-proliferation and survival assays in culture systems, PI3K/Akt and MAPK signaling research, comparative work alongside native IGF-1 and other IGF-1 analogs, and structure-activity studies of the intramolecular disulfide bridges. Investigators have also characterized IGF-1 LR3 in studies probing receptor crosstalk with the insulin receptor and in screening assays for IGF-1R-selective ligand discovery. Use in laboratory research extends to cell-culture growth-factor paradigms where the analog serves as a defined IGF-1R agonist with reduced IGFBP-mediated sequestration. The reference standard is supplied for these and equivalent in-vitro experimental contexts only, with no associated guidance for human, clinical, or veterinary application.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Disulfide-bond integrity is confirmed by reduction-and-alkylation mass spectrometry methods when included in the lot's release specification — an important parameter given the three intramolecular disulfide bridges essential for IGF-1R-engagement-competent folding. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in dilute acidic buffer (consistent with native IGF-1 best practice) or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. The intramolecular disulfide bridges are sensitive to reducing conditions — avoid reductant-containing buffers unless specifically required by the assay. Avoid repeated freeze-thaw cycles of reconstituted material. These handling parameters reflect general best-practice for cysteine-rich peptide reference standards and do not constitute preparation guidance for human or veterinary application.